Evidence map›Paper›PMID 31646427›Full record

ArticleMolecular biology reports2019

Encapsulation of crocetin into poly (lactic-co-glycolic acid) nanoparticles overcomes drug resistance in human ovarian cisplatin-resistant carcinoma cell line (A2780-RCIS).

Navid Neyshaburinezhad, Fatemeh Kalalinia, Maryam Hashemi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Bacterioruberin fromInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Preparation ofPharmaceutics · 2023
    Article
  6. Review
  7. Article
  8. Crocetin: A Systematic Review.Frontiers in pharmacology · 2021
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Navid NeyshaburinezhadDivision of Biopharmaceutics and Pharmacokinetics, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-6651-6988
Fatemeh KalaliniaBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. kalaliniaf@mums.ac.ir.
Maryam HashemiNanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran. Hashemim@mums.ac.ir.ORCID http://orcid.org/0000-0003-1549-4886
Mashhad University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

Mashhad University of Medical Sciences 931570
6 · The paper itself

Abstract

Nanoparticles and herbal medicines have gained considerable attention in overcoming multidrug resistance through different mechanisms. In this study, the effects of poly (Lactic-co-glycolic acid)-crocetin nanoparticles (PLGA-Crt NPs) on MRP

Indexed as

ATP-Binding Cassette, Sub-Family C ProteinsCarotenoidsCell Line, TumorCell ProliferationCell SurvivalCisplatinDose-Response Relationship, DrugDown-RegulationDrug CompoundingDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMultidrug Resistance-Associated Protein 2Ovarian NeoplasmsPolylactic Acid-Polyglycolic Acid CopolymerABCC2 protein, humanATP-Binding Cassette, Sub-Family C ProteinsCarotenoidsCisplatinMultidrug Resistance-Associated Protein 2Polylactic Acid-Polyglycolic Acid Copolymertrans-sodium crocetinateVitamin AA2780A2780-RCISCrocetinOvarian cancer cell linePLGA-crocetin nanoparticles

Identifiers

PMID31646427
OpenAlexW2981546413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.